Minervax ApS

Minervax ApS, based in Copenhagen, Denmark, focuses on developing innovative vaccines, particularly targeting Group B Streptococcus (GBS) infections, to improve maternal and geriatric healthcare outcomes. Minervax ApS specializes in vaccine development aimed at preventing Group B Streptococcus infections. Founded in 2010 in Copenhagen, Denmark, the company has completed 16 investment deals, raising a total of EUR 54. 00 mn in its latest funding round led by prominent investors including Adjuvant Capital and Novo Holdings.

The CEO, Per Fischer, guides the company through advanced clinical phases of its lead product, AlpN GBS. Minervax specializes in the clinical development of innovative vaccines, primarily targeting Group B Streptococcus (GBS) infections. Their core product, AlpN GBS, is a prophylactic vaccine designed for pregnant women and older adults, aiming to prevent adverse pregnancy outcomes and severe infections that can result from GBS. The vaccine is currently advancing towards Phase 3 clinical trials, indicating a commitment to addressing critical unmet medical needs in maternal and geriatric healthcare.

Minervax's clientele includes healthcare providers, hospitals, and governmental health organizations in regions such as Europe and North America, focusing on public health improvements. Minervax has successfully raised nearly EUR 200 mn through investor syndicates, grants, and loans to support the development of its vaccine candidates. Revenue is expected to primarily come from partnerships with healthcare institutions for the procurement of their vaccine, once regulatory approval is achieved. Their business model involves B2B transactions, collaborating with pharmaceutical distributors and healthcare providers to facilitate vaccine distribution, alongside contracts and grants that support ongoing research and clinical trials.

Specific pricing structures for their vaccines are not disclosed. Minervax plans to utilize recent funding to further develop their lead vaccine candidate, AlpN GBS, and aims to expand into new markets, particularly in North America and Europe, by 2024. The focus remains on advancing towards commercialization, with potential new products being designed to address additional health concerns. The recent investment from Kinled Holding will support these growth initiatives, enhancing their capabilities to bring innovative healthcare solutions to market.